StockData
Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc. (LIPO) stock

LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 6/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.27KP/E –Yield –

Lipella Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lipella Pharmaceuticals's operating income for the twelve months ending Sep 30, 2025 was -$5.41M. For fiscal 2024 it was -$5.08M.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$5.08M–
FY2023Dec 31, 2023-$4.75M–
FY2022Dec 31, 2022-$2.59M–
FY2021Dec 31, 2021-$1.92M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025-$1.27M–
Q2 FY2025Jun 30, 2025-$1.36M–
Q1 FY2025Mar 31, 2025-$1.33M–
Q4 FY2024Dec 31, 2024-$1.45M–
Q3 FY2024Sep 30, 2024-$1.46M–
Q2 FY2024Jun 30, 2024-$952.19K–
Q1 FY2024Mar 31, 2024-$1.22M–
Q4 FY2023Dec 31, 2023-$729.59K–
Q3 FY2023Sep 30, 2023-$1.36M–
Q2 FY2023Jun 30, 2023-$1.58M–
Q1 FY2023Mar 31, 2023-$1.08M–
Q4 FY2022Dec 31, 2022-$359.26K–
Q3 FY2022Sep 30, 2022-$712.64K–
Q2 FY2022Jun 30, 2022-$781.15K–
Q1 FY2022Mar 31, 2022-$736.66K–

More Lipella Pharmaceuticals figures

See a number that looks wrong?